电话:
400-7060-959
传真:
+86 10 56315212-8813
电子邮件:
orders@antibodies-online.cn

PKM1-Specific 抗体

适用: 人, 小鼠, 大鼠 IF, IHC, WB, ELISA, IP 宿主: 兔 Polyclonal unconjugated
产品编号 ABIN7117542
发货至: 中国
  • 抗原
    PKM1-Specific
    适用
    人, 小鼠, 大鼠
    宿主
    • 1
    克隆类型
    • 1
    多克隆
    标记
    • 1
    非结合性
    应用范围
    Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB), ELISA, Immunoprecipitation (IP)
    纯化方法
    Immunogen affinity purified
    纯度
    ≥95 % as determined by SDS-PAGE
    免疫原
    PKM2 pyruvate kinase, muscle
    亚型
    IgG
  • 应用备注
    WB: 1:500-1:2000, IP: 1:500-1:2000, IHC: 1:100-1:400, IF: 1:20-1:200
    限制
    仅限研究用
  • 状态
    Liquid
    缓冲液
    PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
    储存液
    Sodium azide
    注意事项
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    储存条件
    -20 °C
    储存方法
    -20°C for 12 months (Avoid repeated freeze / thaw cycles.)
    有效期
    12 months
  • 抗原
    PKM1-Specific
    别名
    PKM1
    背景
    Synonyms:CTHBP, OIP 3, OIP3, Opa interacting protein 3, p58, PK2, PK3, PKM, PKM1, PK-M1, PKM1 pyruvate kinase, muscle, Pyruvate kinase 2/3, Pyruvate kinase isozymes M1/M2, Pyruvate kinase muscle isozyme, TCB, THBP1, Tumor M2 PK Background:PKM, also named as OIP3, PK2, PK3, PKM, p58, THBP1, CTHBP and Tumor M2-PK, belongs to the pyruvate kinase family. It is glycolytic enzyme that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate(PEP) to ADP, generating ATP. It stimulates POU5F1-mediated transcriptional activation. PKM plays a general role in caspase independent cell death of tumor cells. PKM has 2 isoforms named PKM1 and PKM2. By the upstream metabolite fructose-1,6-bisphosphate, PKM1 is a constitutively active enzyme.The primary pyruvate kinase isoform before tumour development is PK-M1, however, the primary isoform from four independent tumours is PK-M2(PMID:18337823). This antibody is specific to PKM1 isoform.
    分子量
    58KD
    UniProt
    P14618
You are here: